Renin Inhibitors: Novel Agents for Renoprotection or a Better Angiotensin Receptor Blocker for Blood Pressure Lowering?

Cardiology Clinics

Volumn 26, Issue 4, 2008, Pages 527-535

  Pimenta, Eduardo ^a   Oparil, Suzanne ^b  

^a INSTITUTO DANTE PAZZANESE DE CARDIOLOGIA   (Brazil)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Hypertension; Renin inhibitors; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; ATORVASTATIN; CAPTOPRIL; CELECOXIB; CGP 38560; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; ENALKIREN; HYDROCHLOROTHIAZIDE; IRBESARTAN; METFORMIN; MEVINOLIN; PEPSTATIN; RAMIPRIL; REMIKIREN; RENIN; RENIN INHIBITOR; VALSARTAN; WARFARIN; ZANKIREN;

ANTIHYPERTENSIVE THERAPY; DIASTOLIC BLOOD PRESSURE; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; HUMAN; HYPERTENSION; IC 50; KIDNEY DYSFUNCTION; MICROALBUMINURIA; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RENIN RELEASE; REVIEW; SYSTOLIC BLOOD PRESSURE;

AMIDES; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; FUMARATES; HUMANS; HYPERTENSION; RENIN;

EID: 53249125114     PISSN: 07338651     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccl.2008.06.003     Document Type: Review

References (50)

1. Pimenta E, Oparil S. Etiology and pathogenesis of systemic hypertension. In: Crawford MH, DiMarco JP, Paulus WJ, editors. Cardiology, 3rd edition. London: Mosby, in press.
2. Danser A.H., and Denium J. Renin, pro-renin and putative (Pro)renin receptor. Hypertension 46 (2005) 1069-1076
3. Reudelhuber T.L., Ramla D., Chiu L., et al. Proteolytic processing of human pro-renin in renal and non-renal tissues. Kidney Int 46 (1994) 1522-1524
4. Danser A.H., Derkx F.H., Schalekamp M.A., et al. Determinants of interindividual variation of renin and pro-renin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 16 (1998) 853-862
5. Luetscher J.A., Kraemer F.B., Wilson D.M., et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complication. N Engl J Med 312 (1985) 1412-1417
6. Price D.A., Porter L.E., Gordon M., et al. The paradox of the low-renin state in diabetic nephropaty. J Am Soc Nephrol 10 (1999) 2382-2391
7. Bühler F.R., Laragh J.H., Vaughan E.D., et al. Antihypertensive action of propranolol: specific anti-renin responses in high and normal renin forms of essential, renal, renovascular and malignant hypertension. Am J Cardiol 32 (1973) 511-522
8. Michelakis A.M., and McAllister R.G. The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab 34 (1972) 386-394
9. Ondetti M.A. Design of specific inhibitors of angiotensin-converting enzyme: new class of orally active antihypertensive agents. Science 196 (1977) 441-444
10. Ferreira S.H. A bradykinin-potentiating factor present in the venom of Bothrops jararaca. Br J Pharmacol 24 (1965) 163-169
11. Ferreira S.H., and Greene X. Isolation of bradykinin-potentiating peptides from Bothrops jararaca venom. Biochemistry 9 (1970) 2583-2593
12. Tigerstedt R., and Bergman P.G. Niere und Kreislauf. Skand Arch Physiol 8 (1898) 223-271
13. Gradman A.H., and Kad R. Renin inhibition in hypertension. J Am Coll Cardiol 51 (2008) 519-528
14. Pils B., Shagdarsuren E., Wellner M., et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46 (2005) 569-576
15. Azizi M., Webb R., Nussberger J., et al. Renin inhibition with aliskiren: where are we now, and where are we going?. J Hypertens 24 (2006) 243-256
16. Michel J.B., Galen F.X., Guettier C., et al. Immunological approach to blockade of the renin-substrate reaction. J Hypertens 7 (1989) S63-S70
17. Gross F., Lazar J., and Orth H. Inhbition of the renin-angiotensinogen reaction by pepstatin. Science 175 (1972) 656
18. Evin G., Gardes J., Kreft C., et al. Soluble pepstatins: a new approach to blockade in vivo of the renin angiotensin system. Clin Sci 55 (1978) 167s-171s
19. Eid M., Evin G., Castro B., et al. New renin inhibitors homologous with pepstatin. Biochem J 197 (1981) 465-471
20. Boger J., Lohr N.S., Ulm E.H., et al. Novel renin inhibitors containing the amino acid statine. Nature 303 (1983) 81-84
21. Zusman R.M., Burton J., Christensen D., et al. Hemodynamic effects of a competitive renin in inhibitory peptide in humans. Evidence for multiple mechanisms of action. Trans Assoc Am Physicians 96 (1983) 365-374
22. Macfayden R.J., Jones C.R., Doig J.K., et al. Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans. J Cardiovasc Pharmacol 25 (1995) 347-353
23. Rongen G.A., Lenders J.W., Smits P., et al. Clinical pharamacokinetics and efficacy of renin inhibitors. Clin Pharmacokinet 29 (1995) 6-14
24. Himmelmann A., Bergbrant A., Svensson A., et al. Remikiren (Ro 42-5892)-an orally active renin inhibitor in essential hypertension. Effects on blood pressure and the renin-angiotensin-aldosterone system. Am J Hypertens 9 (1996) 517-522
25. Ménard J., Boger R.S., Moyse D.M., et al. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in mildly sodium-depleted normotensive subjects. Circulation 91 (1995) 330-338
26. Rongen G.A., Lenders J.W., Kleinbloesem C.H., et al. Efficacy and tolerability of the renin inhibitor Ro 42-5892 in patients with hypertension. Clin Pharmacol Ther 54 (1993) 567-577
27. Camenzind E., Nussberger J., Juillerat L., et al. Effect of the renin response during renin inhibition: oral Ro 42-5892 in normal humans. J Cardiovasc Pharmacol 18 (1991) 299-307
28. Delabays A., Nussberger J., Porchet M., et al. Hemodynamic and humoral effects of the new renin inhibitior enalkiren in normal humans. Hypertension 13 (1989) 941-947
29. Weber M.A., Neutel J.M., Essinger I., et al. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor. Circulation 81 (1990) 1768-1774
30. Neutel J.M., Luther R.R., Boger R.S., et al. Immediate blood pressure effects of the renin inhibitor enalkiren and the ACE inhibitor enalaprilat. Am Heart J 122 (1991) 1094-1100
31. Van den Meiracker A.H., Admiraal P.J., Man in't Veld A.J., et al. Prolonged blood pressure reduction by orally active renin inhibitor RO-42-5892 in essential hypertension. Br Med J 301 (1990) 205-210
32. Jeunemaitre X., Menard J., Nussberger J., et al. Plasma angiotensin, renin and blood pressure during acute renin inhibition by GCP 38 560A in hypertensive patients. Am J Hypertens 2 (1989) 819-827
33. Staessen J.A., Li Y., and Richart T. Oral renin inhibitors. Lancet 368 (2006) 1449-1456
34. Nussberger J. Renin inhibitors. In: Oparil S., and Weber M.A. (Eds). Hypertension: a companion to Brenner and Rector's the kidney. 2nd edition (2005), Elsevier, Philadelphia 754-764
35. Nussberger J., Wuerzner J., Jensen C., et al. Angiotensin II supression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril. Hypertension 39 (2002) e1-e8
36. Dieterle W., Corynen S., Vaidyanathan S., et al. Effect of the oral renin inhibitor aliskiren on the pharmacokinetics and pharmacodynamics of a single dose of warfarin in healthy subjects. Br J Clin Pharmacol 58 (2004) 433-436
37. Dieterle W., Corynen S., Vaidyanathan S., et al. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 43 (2005) 527-535
38. Dieterich H., Kemp C., Vaidyanathan S., et al. Pharmacokinetic interaction of the oral renin inhibitor aliskiren with hydrochlorothiazide in healthy volunteers. Clin Pharmacol Ther 79 (2006) P12 [abstract]
39. Dieterich H., Kemp C., Vaidyanathan S., et al. Aliskiren, the first in a new class or orally effective renin inhibitors, has no clinically significant drug interactions with digoxin in healthy volunteers. Clin Pharmacol Ther 79 (2006) P64 [abstract]
40. Azizi M., Ménard J., Bissery A., et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 15 (2004) 3126-3133
41. Shagdarsuren E., Wellner M., Braesen J.H., et al. Complement activation in angiotensin II-induced organ damage. Circ Res 97 (2005) 716-724
42. Kelly D.J., Zhang Y., Moe G., et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropaty in rats. Diabetologia 50 (2007) 2398-2404
43. Persson F., Rossing P., Schjoedt K.J., et al. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. Kidney Int 73 12 (2008) 1419-1425
44. Gradman A.H., Schmieder R.E., Lins R.L., et al. Aliskiren, a novel orally effective rennin inhibitor, provides dose-dependent antihypertensive efficacy and placebo-like tolerability in hypertensive patients. Circulation 111 (2005) 1012-1018
45. Oh B.H., Mitchell J., Herron J.R., et al. Aliskiren, an oral rennin inhibitor, provides dose-dependent efficacy and sustained 24-h blood pressure control in patients with hypertension. J Am Coll Cardiol 49 (2007) 1157-1163
46. Dahlöf B., Anderson D.R., Arora V., et al. Aliskiren, a direct renin inhibitor, provides antihypertensive efficacy and excellent tolerability independent of age or gender in patients with hypertension. J Clin Hypertens 9 (2007) A157 [abstract]
47. Andersen K., Weinberger M.H., Egan B., et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 26 (2008) 589-599
48. Villamil A., Chysant S.G., Calhoun D., et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 25 (2007) 217-226
49. Oparil S., Yarows S.A., Patel S., et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomized double-blind trial. Lancet 370 (2007) 221-229
50. Sealey J.E., and Laragh J.H. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 20 (2007) 587-597